Report : North America Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type (Vitamin D and Calcium Supplement, Protein Supplement, Vitamin B12 Supplement, and Others) and Distribution Channel (Pharmacies, Retail Channels, Online Channels, and Others)
At 5.8% CAGR, North America Sarcopenia Treatment Market is Projected to be Worth US$ 2,273.85 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the North America sarcopenia treatment market was valued at US$ 1,451.12 million in 2022 and is expected to reach US$ 2,273.85 million by 2030, registering a CAGR of 5.8% from 2022 to 2030. Upsurge in geriatric population and rising awareness about sarcopenia are among the critical factors attributed to drive the North America sarcopenia treatment market growth.
The growing awareness of sarcopenia and its negative impact on health presents a significant scope for advancements in the fields of healthcare and geriatric care. Many advocacy groups and organizations are proactively taking steps to raise the awareness of sarcopenia among the masses. These organizations often work with medical professionals to keep the public updated on the various aspects of certain disorders, such as pathogenicity, target patients, prevention, and treatments, along with underlining the value of prompt diagnosis and treatment. The Office on Women's Health (OWH) of the US Department of Health and Human Services launched the national campaign "Stronger than Sarcopenia" in 2023 to magnify the awareness of sarcopenia in women. Research by Health and Human Services shows that more than 45% of the elderly population in the US suffers from sarcopenia, and millions of younger individuals are at risk of developing this condition later in their lives. In line with OWH's "Stronger than Sarcopenia" campaign, women are urged to discuss sarcopenia with their healthcare providers, followed by undergoing screen for the illness and taking appropriate therapy if required.
Sarcopenia has been included in the curricula of medical schools and training programs for healthcare professionals such as physicians, nurses, and physical therapists. For example, the OWH worked with Medscape Education to create continuing medical education (CME) credits for healthcare professionals, which will better equip them to detect and treat sarcopenia in their patients. Mainstream media has expanded its coverage of sarcopenia to include articles, news stories, and documentaries. According to a February 2022 PubMed article, the US Department of Health and Human Services is one of the top funding agencies in the US, sponsoring 1,604 studies on sarcopenia. From 2022, July 4th is observed as the World Sarcopenia Day. Thus, the elevating awareness regarding sarcopenia is likely to bring new growth trends into the sarcopenia treatment market in the coming years.
On the contrary, unavailability of direct interventions hampers the growth of North America sarcopenia treatment market.
Based on treatment type, the North America sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held 40.6% share of North America sarcopenia treatment market in 2022, amassing US$ 589.72 million. It is projected to garner US$ 987.96 million by 2030 to register 6.7% CAGR during 2022-2030.
In terms of distribution channel, the North America sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held 39.2% share of North America sarcopenia treatment market in 2022, amassing US$ 569.55 million. It is anticipated to garner US$ 857.04 million by 2030 to expand at 5.2% CAGR during 2022-2030.
Based on country, the North America sarcopenia treatment market is categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 77.0% share of North America sarcopenia treatment market in 2022. It was assessed at US$ 1,117.22 million in 2022 and is likely to hit US$ 1,790.66 million by 2030, registering a CAGR of 6.1% during 2022-2030.
Key players operating in the North America sarcopenia treatment market are Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, GSK Plc, and Makers Nutrition LLC, among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com